WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012109353) GROWTH HORMONE RECEPTOR DEFICIENCY CAUSES A MAJOR REDUCTION IN PRO-AGING SIGNALING, CANCER AND DIABETES IN HUMANS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/109353    International Application No.:    PCT/US2012/024326
Publication Date: 16.08.2012 International Filing Date: 08.02.2012
IPC:
G01N 33/68 (2006.01), C12Q 1/68 (2006.01), G01N 33/53 (2006.01)
Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; USC Stevens 3740 McClintock Avenue Hughes Center, Suite EEB131 Los Angeles, California 90089-2561 (US) (For All Designated States Except US).
LONGO, Valter D. [US/US]; (US) (For US Only)
Inventors: LONGO, Valter D.; (US)
Agent: PROSCIA, James W.; Brooks Kushman P.C. 1000 Town Center Twenty-Second Floor Southfield, Michigan 48075 (US)
Priority Data:
61/462,823 08.02.2011 US
Title (EN) GROWTH HORMONE RECEPTOR DEFICIENCY CAUSES A MAJOR REDUCTION IN PRO-AGING SIGNALING, CANCER AND DIABETES IN HUMANS
(FR) UNE DÉFICIENCE EN RÉCEPTEUR DE L'HORMONE DE CROISSANCE PROVOQUE UNE RÉDUCTION MAJEURE DANS LA SIGNALISATION PRO-VIEILLISSEMENT, LE CANCER ET LE DIABÈTE CHEZ LES ÊTRES HUMAINS
Abstract: front page image
(EN)A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as chemotherapy related symptoms. A method of alleviating oxidative damage, cellular damage including mutations, and insulin resistance in a subject is also provided.
(FR)L'invention concerne une méthode d'atténuation d'un symptôme de la chimiothérapie chez un sujet, comprenant l'identification d'un sujet soumis à une chimiothérapie puis l'administration d'une quantité thérapeutiquement efficace d'une composition inhibitrice de l'axe GH/IGF-1 au sujet. Typiquement, les taux de IGF-1 et/ou de GH chez le sujet sont mesurés, ainsi que les symptômes liés à la chimiothérapie. L'invention concerne également un procédé de diminution des dommages oxydatifs, des dommages cellulaires, notamment des mutations, et de l'insulinorésistance chez un sujet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)